Read about new melanoma treatment practices, how models provide information about a rare adrenal cancer, a potential oral medication for brain cancer, and clinical trials for cancer patients with HIV.
Scientists have spent years trying to develop an effective HIV vaccine, but none have proven successful. Based on findings from a recently published study, a Johns Hopkins Medicine-led research team may have put science one step closer to that goal.
Skin cancer is the most prevalent form of cancer in the United States, with over 5 million cases diagnosed annually. The Centers for Disease Control and Prevention reports that melanoma alone accounts for more than 8,000 deaths each year. Thankfully, skin cancer is highly preventable, making it crucial to prioritize protection. Below are some of the latest headlines in the Dermatology channel.
An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor.
New research from Boston Medical Center found that people living with HIV that have had pulmonary tuberculosis had broader and more potent HIV antibody responses and differences in HIV sequences predicted to be antibody resistant as compared to those without suspected or documented tuberculosis.
Uganda’s anti-homosexuality bill, if signed into law, could lead to the withdrawal of foreign aid and threaten goals to end HIV/AIDS by 2030, advocates warn.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
Gene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells – can effectively eliminate HIV infection. The study is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.
Not for public release
This news release is embargoed until 1-May-2023 5:00 PM EDT
Released to reporters: 25-Apr-2023 2:00 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 1-May-2023 5:00 PM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.
UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CART-cell therapy.
Not for public release
This news release is embargoed until 14-Apr-2023 11:00 AM EDT
Released to reporters: 12-Apr-2023 1:15 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 14-Apr-2023 11:00 AM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Below are some of the latest headlines in the new Avian Flu channel on Newswise.
Not for public release
This news release is embargoed until 12-Apr-2023 2:40 PM EDT
Released to reporters: 12-Apr-2023 2:40 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 12-Apr-2023 2:40 PM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
The National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.45 million grant to the San Diego Center for AIDS Research at UC San Diego, renewing support that extends back to an original establishing grant in 1994 at the height of the AIDS epidemic.
Wistar Institute researchers identified hopeaphenol, a natural plant-based compound, as possessing antiviral properties that are effective against HIV.
Countries must intensify efforts to track HIV and hepatitis C virus (HCV) incidence among people who inject drugs, and to prioritise this group in prevention and elimination work, according to new University of Bristol-led research, published online in The Lancet Gastroenterology & Hepatology.
A quick, affordable diagnostic test developed by a Washington State University researcher may help curb one of the most prevalent but least discussed sexually transmitted infections.
To develop treatments that may one day entirely rid the body of HIV infection, scientists have long sought to identify all of the places that the virus can hide its genetic code. Now, in a study using blood samples from men and women with HIV on long-term suppressive therapy, a team led by Johns Hopkins Medicine scientists reports new evidence that one such stable reservoir of HIV genomes can be found in circulating white blood cells called monocytes.
MitoQ, a mitochondrial antioxidant that is available to the public as a diet supplement, was found in a mouse study to reverse the detrimental effects that HIV and antiretroviral therapy (ART) have on mitochondria in the brain, heart, aorta, lungs, kidney and liver.
A new study from Boston University Chobanian & Avedisian School of Medicine has found that a brief stigma intervention that specifically targets people with HIV who inject drugs was effective in increasing engagement in substance use care as well as improving their ART adherence.
Staphylococcus aureus, Clostridioides difficile, Candida auris, Drug-resistant Shigella. These bacteria not only have difficult names to pronounce, but they are also difficult to fight off. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antimicrobial resistance is an urgent global public health threat.
Infectious diseases like COVID, HIV, and battlefield wound infections cause illness and disruptions that threaten health and military readiness across the nation. To help foster collaboration in the field and share best practices, the Uniformed Service University’s (USU) Infectious Disease Clinical Research Program (IDCRP) is hosting its first annual Science Symposium March 6-10.
Case Western Reserve University (CWRU) has completed an exclusive license agreement with Atlanta-based RORA Biologics Inc. (RORA-Bio) for intellectual property to develop new therapies to treat HIV and certain kinds of cancer.
Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.
A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.
A recent study performed in Zambia by University of Maryland School of Medicine’s (UMSOM) Institute of Human Virology researchers found that high uptake of HIV preventative medicine, known as pre-exposure prophylaxis (PrEP), is possible in prison populations with adequate resources and support from the criminal justice health system.
The National Institutes of Health has awarded $3.8 million to Texas Biomedical Research Institute to further develop a promising HIV vaccine candidate that stops the virus upon entry, before it begins rapidly spreading throughout the body.
Since 2017, the lab of Rahima Benhabbour, PhD, MSc, associate professor in the UNC/NCSU Joint Department of Biomedical Engineering, has been working with a research team at the Centers for Disease Control and Prevention (CDC) and others at UNC to develop an injectable implant that can release HIV pre-exposure prophylaxis (PrEP) medications into the body for a long period of time.
Their latest research, published in Nature Communications, shows that the team’s latest formulation can provide up to six months of full protection.
Failing to address the psychological trauma experienced by many older people living with HIV/AIDS will make it difficult, if not impossible, to end the epidemic, according to a Rutgers study.
Comprehensive and inclusive sexual health education reduces young gay, bisexual, and queer (GBQ) men's vulnerability to poor sexual health outcomes like HIV and STIs into adulthood, data shows. However, conservative ideologies continue to dominate policies on school-based sex education and view topics like same-sex attractions as controversial.
Florida State University has been awarded a $72.7 million grant from the National Institutes of Health (NIH) to redesign and improve HIV prevention and care interventions in adolescents and young adults in the United States. Under the grant, which will be dispersed over the course of seven years, FSU will serve as the Scientific Leadership Center (SLC) for the Adolescent Medicine Trials Network for HIV Interventions.
UNC-Chapel Hill scientists and colleagues provide indirect evidence for the existence of a distinct latent reservoir of CD4+ T cells in the central nervous system, by analyzing rebound virus in the cerebral spinal fluid during the period when people had just stopped taking ART.
A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.
Using a crowdsourcing framework utilized over the past five years, Juliet Iwelunmor, Ph.D., professor of global health and behavioral science and health education at Saint Louis University’s College for Public Health and Social Justice, is taking what she learned from empowering youth in Nigeria to identify young people in the United States who aim to become the next generation of HIV researchers, leaders and innovators in the field.
Moffitt Cancer Center, Weill Cornell Medicine and the University of North Carolina School of Medicine have received a $3.5 million, five-year grant from the National Cancer Institute (NCI) to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
Researchers in University at Albany’s Center for Behavioral Health Promotion and Applied Research in the School of Education have received funding to undertake a new project aimed at reducing risk for suicide and substance use among students experiencing health disparities. The work aims to hone strategies that could be implemented widely across college campuses.
Black sexual minority men who give and receive support within their social networks are more likely to be tested for syphilis. Therefore, nurses should prepare patients to inform and encourage their social networks to seek testing for syphilis, HIV, and other sexually transmitted infections (STIs). These conclusions come from a paper in the January issue of The Journal of the Association of Nurses in AIDS Care (JANAC), the official journal of the Association of Nurses in AIDS Care. JANAC is published in the Lippincott portfolio by Wolters Kluwer.
amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years.
New UCLA-led research suggests that antiretroviral drugs called TAF and TDF directly reduce energy production by mitochondria, structures inside cells that generate the power that cells use to function. Both drugs led to reduced cellular oxygen consumption rates, a measure of the ability of the mitochondria to produce energy, compared with controls.
A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV.